Skip to main content
. 2020 Sep 17;20:371. doi: 10.1186/s12886-020-01637-0

Table 3.

Number of additional injections (from month 3 to 6) in 3-month nonresponder patients based on the response at 6 months

6-month induction vs
3-month induction
Additional injections Additional injections in responder patients Additional injections in nonresponder patients
Aflibercept (Eylea®) 289.57 109.57 180
Ranibizumab (Lucentis®) 208.98 61.98 219
Bevacizumab (Avastin®) 393.56 39.56 354